Dolutegravir: A new option for HIV treatment

Alessia Carbone, Adriano Lazzarin, Antonella Castagna

Research output: Contribution to journalArticlepeer-review


The need for new strategies for treating HIV-1 infection has led to the development of a number of new drugs. The aim of this article is to review the latest results of clinical trials of dolutegravir, an integrase inhibitor whose efficacy, tolerability and safety have been confirmed in treatment-naive and treatment-experienced patients. The findings, together with its high genetic barrier and limited interactions with other drugs, indicate that dolutegravir will play an important role in the future treatment of HIV infection.

Original languageEnglish
Pages (from-to)801-810
Number of pages10
JournalFuture Virology
Issue number9
Publication statusPublished - Sep 1 2014


  • antiretroviral therapy
  • dolutegravir
  • HIV-1
  • integrase
  • treatment-experienced patients
  • treatment-naive patients

ASJC Scopus subject areas

  • Virology


Dive into the research topics of 'Dolutegravir: A new option for HIV treatment'. Together they form a unique fingerprint.

Cite this